ripekg:evaluation/RIPEA148131811A593CED |
prov:used |
ripekg:study-design-evidence/RIPEA148131811A593CED |
ripekg:study-design-evidence/RIPEA148131811A593CED |
rdf:type |
rdfs:Resource |
ripekg:study-design-evidence/RIPEA148131811A593CED |
rdf:type |
owl:Thing |
ripekg:study-design-evidence/RIPEA148131811A593CED |
rdf:type |
ripe:IntegrityAssessmentEvidenceIntegrity assessment evidence |
ripekg:study-design-evidence/RIPEA148131811A593CED |
rdf:type |
ripe:StudyDesignEvidenceStudy design evidence |
ripekg:study-design-evidence/RIPEA148131811A593CED |
rdf:type |
tido:Evidence |
ripekg:study-design-evidence/RIPEA148131811A593CED |
prov:wasGeneratedBy |
ripekg:evidence-aggregation/RIPEA148131811A593CED |
ripekg:study-design-evidence/RIPEA148131811A593CED |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA148131811A593CED |
ripekg:study-design-evidence/RIPEA148131811A593CED |
ripe:concerns |
ripekg:work/10.1136%2Fbmj-2024-083382Prevention of acute myocardial infarction induced heart failure by intracoronary infusion of mesenchymal stem cells: phase 3 randomised clinical trial (PREVENT-TAHA8) |
ripekg:study-design-evidence/RIPEA148131811A593CED |
ripe:concerns |
ripekg:work/10.1136%2Fbmj-2024-083382e083382 | the bmj Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies |
ripekg:study-design-evidence/RIPEA148131811A593CED |
ripe:recruitmentEndDateExtractionRationale |
No direct LPI; range end is not used for recruitment_finish. |
ripekg:study-design-evidence/RIPEA148131811A593CED |
ripe:recruitmentStartDate |
09-2021 |
ripekg:study-design-evidence/RIPEA148131811A593CED |
ripe:recruitmentStartDateExtractionRationale |
Methods: '...trial is a single blinded, randomised, phase 3 superiority trial conducted from September 2021 to October 2024.' Used start of conducted range as recruitment_start per rule 5; no specific FPI elsewhere. |
ripekg:study-design-evidence/RIPEA148131811A593CED |
ripe:studyEndDate |
10-2024 |
ripekg:study-design-evidence/RIPEA148131811A593CED |
ripe:studyEndDateExtractionRationale |
Methods: '...trial is a single blinded, randomised, phase 3 superiority trial conducted from September 2021 to October 2024.' Used end of conducted range as study_end_date per rule 5; no specific completion date. |
ripekg:study-design-evidence/RIPEA148131811A593CED |
tido:supports |
ripekg:integrity-assessment-hypothesis/RIPEA148131811A593CED-human-2-2 |
ripekg:study-design-evidence/RIPEA148131811A593CED |
tido:supports |
ripekg:integrity-assessment-hypothesis/RIPEA148131811A593CED-inspectai-2-2 |